Alpha Cognition (ACOG) vs Compass Therapeutics (CMPX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Alpha Cognition (ACOG) has outperformed Compass Therapeutics (CMPX) over the past year, gaining 20.4% versus a loss of 79.8%. Alpha Cognition is the larger company by market cap ($178.4 million vs $154.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACOG | CMPX |
|---|---|---|
| Share price | $8.19 | $0.86 |
| Market cap | $178.36M | $154.88M |
| 1-day change | -3.08% | -4.09% |
| YTD return | +26.00% | -83.99% |
| 1-year return | +20.44% | -79.81% |
| 5-year return | — | -73.54% |
| EPS (TTM) | $-1.32 | $-0.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $10.22M | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-20.67M | $-66.49M |
| Gross margin | 94.10% | — |
| Operating margin | -221.72% | — |
| Net margin | -202.24% | — |
| 52-week high | $10.14 | $6.88 |
| 52-week low | $4.50 | $0.822 |
| Distance from 52-week high | -19.23% | -87.50% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +119.78% | +533.72% |
| Average volume | 127.06K | 4.30M |
| Shares outstanding | 21.78M | 180.09M |
| Employees | 71 | 39 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACOG has outperformed CMPX by 100.3 percentage points over the past year.
About Alpha Cognition
ACOG stock →Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease.
Healthcare · Biotechnology · 71 employees
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Healthcare · Biotechnology · 39 employees
ACOG vs CMPX FAQ
Which is bigger, Alpha Cognition or Compass Therapeutics?
Alpha Cognition (ACOG) is larger, with a market capitalization of $178.36M compared with $154.88M for Compass Therapeutics (CMPX).
Which stock has performed better over the past year, ACOG or CMPX?
ACOG returned +20.44% over the past 12 months, compared with -79.81% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Alpha Cognition and Compass Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.